

**Date: February 02, 2021**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited,</b> Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited, (BSE)</b> Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
<b>Symbol – LINCOLN</b>	<b>Scrip Code – 531633</b>

Dear Sir,

**SUB.: OUTCOME OF BOARD MEETING.**

Further to our letter dated January 25, 2021 and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform that the Board of Directors of the Company at their meeting held **today i.e. Tuesday, February 02, 2021**, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter and nine months ended on December 31, 2020.


We also enclose herewith financial highlights of the Company for the aforesaid quarter.

The Meeting of the Board of Directors of the Company commenced at 11:15 p.m. and concluded at 12:30 p.m.

Kindly take the same on your records.

Thanking you,

Yours faithfully,  
**For Lincoln Pharmaceuticals Limited**

  
**Niren A. Desai**  
**Company Secretary**



Encl: A/a

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter and Nine-Months Ended on 31-December-2020.

PART-I		(Amt. In Lakhs)					
Sr. No.	Particulars	Quarter Ended			Nine-Months Ended		Year Ended
		31/12/2020 (Un-Audited)	30/09/2020 (Un-Audited)	31/12/2019 (Un-Audited)	31/12/2020 (Un-Audited)	31/12/2019 (Un-Audited)	31/03/2020 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	11,219.23	12,228.95	9,563.99	33,551.45	30,082.63	37,608.83
	B) Other Income	106.46	121.95	236.62	425.90	682.17	1,213.09
	<b>Total Income</b>	<b>11,325.69</b>	<b>12,350.90</b>	<b>9,800.61</b>	<b>33,977.35</b>	<b>30,764.80</b>	<b>38,821.92</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	2,920.74	2,738.25	2,772.81	7,669.37	8,151.68	10,197.06
	B) Purchase of Stock-In-Trade	3,199.88	3,254.58	2,613.51	9,127.83	7,280.35	9,066.22
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	52.60	77.63	(446.88)	670.11	(315.29)	(585.50)
	D) Employee Benefits Expenses	1,276.93	1,265.05	1,342.06	3,748.75	4,240.18	5,489.91
	E) Finance Costs	36.11	20.66	45.98	90.43	167.56	198.36
	F) Depreciation and Amortisation Expense	142.22	142.02	141.24	424.79	410.65	546.95
	G) Other Expenses	1,881.53	2,113.44	2,127.12	5,623.79	5,563.22	7,504.26
	<b>Total Expenses</b>	<b>9,510.01</b>	<b>9,611.64</b>	<b>8,595.84</b>	<b>27,355.08</b>	<b>25,498.36</b>	<b>32,417.27</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>1,815.68</b>	<b>2,739.26</b>	<b>1,204.77</b>	<b>6,622.28</b>	<b>5,266.44</b>	<b>6,404.65</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>1,815.68</b>	<b>2,739.26</b>	<b>1,204.77</b>	<b>6,622.28</b>	<b>5,266.44</b>	<b>6,404.65</b>
6	Tax Expense						
	A) Current Tax (Net)	462.00	704.00	210.59	1,702.00	1,269.70	1,470.01
	B) Deferred Tax (Net)	16.85	15.51	(23.57)	64.61	(36.30)	(23.63)
	C) Short / Excess Provision of Income Tax of Previous Years	Nil	Nil	Nil	Nil	Nil	1.92
7	<b>Profit / Loss For The Period (5-6)</b>	<b>1,336.83</b>	<b>2,019.76</b>	<b>1,017.75</b>	<b>4,855.67</b>	<b>4,033.03</b>	<b>4,956.35</b>
8	Attributable to:						
	Non-Controlling Interest	Nil	Nil	Nil	Nil	Nil	Nil
	<b>Owners of the Company</b>	<b>1,336.83</b>	<b>2,019.76</b>	<b>1,017.75</b>	<b>4,855.67</b>	<b>4,033.03</b>	<b>4,956.35</b>
9	Other Comprehensive Income (Net Of Tax)	(10.99)	(10.99)	1.08	(32.96)	3.25	(43.94)
10	<b>Total Comprehensive Income</b>	<b>1,325.84</b>	<b>2,008.77</b>	<b>1,018.84</b>	<b>4,822.71</b>	<b>4,036.29</b>	<b>4,912.41</b>
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
12	Other Equity						28,449.47
13	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
	(a) Basic	6.68	10.10	5.09	24.28	20.17	24.78
	(b) Diluted	6.68	10.10	5.09	24.28	20.17	24.78

## NOTES:

- The Financial Results of the Company for the Quarter and Nine-Months Ended December 31, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on February 02, 2021. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- These Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Parliament of India has approved the Code on Social Security, 2020 ("the Code") which may impact the contributions by the Company towards provident fund, gratuity and ESIC. The Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. Effective date of the code and rules thereunder are yet to be notified. In view of this, the impact of change, if any, will be assessed and recognised post notification of the relevant provisions.
- Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.
- Comparative figures have been re-arranged / re-grouped wherever necessary.

For Lincoln Pharmaceuticals Limited



Place: Ahmedabad  
Date: February 02, 2021

Mahendra G. Patel  
Managing Director  
DIN: 00104706

# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS


**Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To -  
The Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended December 31, 2020 and for the year to date period from April 01, 2020 to December 31, 2020 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place: Ahmedabad**  
**Date: 02/02/2021**

For, J.T. Shah & Co.  
Chartered Accountants  
(Firm Regd. No: 109616W)

  
(J. J. Shah)  
Partner

(M.No.45669)  
UDIN: 21045669AAAABQ1744

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com


Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine-Months Ended on 31-December-2020.

PART-I		(Amt. In Lakhs)					
Sr. No.	Particulars	Quarter Ended			Nine-Months Ended		Year Ended
		31/12/2020 (Un-Audited)	30/09/2020 (Un-Audited)	31/12/2019 (Un-Audited)	31/12/2020 (Un-Audited)	31/12/2019 (Un-Audited)	31/03/2020 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	11,474.71	12,606.43	9,852.39	34,460.50	30,802.37	38,649.05
	B) Other Income	72.92	60.18	303.47	312.90	685.27	1,104.02
	<b>Total Income</b>	<b>11,547.63</b>	<b>12,666.61</b>	<b>10,155.86</b>	<b>34,773.40</b>	<b>31,487.64</b>	<b>39,753.07</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	3,581.69	3,558.06	3,471.55	9,842.05	10,604.20	13,372.62
	B) Purchase of Stock-In-Trade	2,518.43	2,322.63	1,892.05	6,521.27	4,581.24	5,759.95
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	55.24	134.65	(471.78)	907.04	(405.42)	(841.34)
	D) Employee Benefits Expenses	1,380.14	1,362.21	1,424.96	4,034.41	4,490.66	5,865.38
	E) Finance Costs	39.16	(7.86)	134.74	98.69	257.38	201.76
	F) Depreciation and Amortisation Expense	189.59	189.45	188.27	566.86	550.06	732.62
	G) Other Expenses	1,939.03	2,252.45	2,216.53	5,962.27	5,839.73	7,938.84
	<b>Total Expenses</b>	<b>9,703.28</b>	<b>9,811.59</b>	<b>8,856.32</b>	<b>27,932.60</b>	<b>25,917.85</b>	<b>33,029.83</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>1,844.35</b>	<b>2,855.02</b>	<b>1,299.54</b>	<b>6,840.80</b>	<b>5,569.79</b>	<b>6,723.24</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>1,844.35</b>	<b>2,855.02</b>	<b>1,299.54</b>	<b>6,840.80</b>	<b>5,569.79</b>	<b>6,723.24</b>
	Tax Expense						
6	A) Current Tax (Net)	479.99	739.83	248.18	1,803.58	1,353.38	1,566.96
	B) Deferred Tax (Net)	16.03	12.83	(40.78)	60.42	(36.17)	4.03
	C) Short / Excess Provision of Income Tax of Previous Years	Nil	10.13	Nil	10.13	Nil	5.62
7	<b>Profit / Loss For The Period (5-6)</b>	<b>1,348.32</b>	<b>2,092.24</b>	<b>1,092.14</b>	<b>4,966.67</b>	<b>4,252.58</b>	<b>5,146.63</b>
	Attributable to:						
8	Non-Controlling Interest	0.14	1.05	1.04	1.56	3.10	2.71
	<b>Owners of the Company</b>	<b>1,348.18</b>	<b>2,091.19</b>	<b>1,091.09</b>	<b>4,965.11</b>	<b>4,249.48</b>	<b>5,143.92</b>
9	Other Comprehensive Income (Net Of Tax)	(11.55)	(11.55)	0.83	(34.64)	2.48	(46.18)
10	<b>Total Comprehensive Income</b>	<b>1,336.64</b>	<b>2,079.64</b>	<b>1,091.92</b>	<b>4,930.47</b>	<b>4,251.96</b>	<b>5,097.74</b>
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
12	Other Equity						29,308.89
13	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
	(a) Basic	6.74	10.46	5.46	24.83	21.25	25.72
	(b) Diluted	6.74	10.46	5.46	24.83	21.25	25.72

## NOTES:

- The Financial Results of the Company for the Quarter and Nine-Months Ended December 31, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on February 02, 2021. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- These Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Scheme of amalgamation of Lincoln Parenteral Limited ("Transferor Company") with Lincoln Pharmaceuticals Limited ("Transferee Company") and their respective Shareholders and Creditors ("Scheme") have been under consideration with the Hon'ble National Company Law Tribunal, Ahmedabad Bench.
- Savebux Enterprises Private Limited (subsidiary of the Company) have received the final report from the statutory auditor on liquidation, on the basis said report, Insolvency Professional (IP) have started the procedure to file the petition with the Hon'ble National Company Law Tribunal (NCLT).
- The Parliament of India has approved the Code on Social Security, 2020 ("the Code") which may impact the contributions by the Company towards provident fund, gratuity and ESIC. The Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. Effective date of the code and rules thereunder are yet to be notified. In view of this, the impact of change, if any, will be assessed and recognised post notification of the relevant provisions.
- Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.
- Comparative figures have been re-arranged / re-grouped wherever necessary.
- Consolidated Results includes results of its subsidiaries.

For Lincoln Pharmaceuticals Limited



Place: Ahmedabad  
Date: February 02, 2021

Mahendra G. Patel  
Managing Director  
DIN: 00104706

# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

**Limited Review Report on consolidated unaudited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To  
The Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Lincoln Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2020 and for the year to date period from April 01, 2020 to December 31, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - A. Lincoln Pharmaceuticals Limited - Parent Company
  - B. Lincoln Parenteral Limited - Subsidiary Company
  - C. Zullinc Healthcare LLP - Wholly-Owned Subsidiary
  - D. Savebux Enterprises Pvt Ltd (Under Liquidation) Company - Wholly-Owned Subsidiary




# J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects total revenues of Rs.168.14 Lacs, total net profit after tax of Rs.22.23 Lacs for the nine months ended December 31, 2020, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

Place: Ahmedabad  
Date: 02/02/2021



For, J.T. Shah & Co.  
Chartered Accountants  
(Firm Regd. No: 109616W)

(J. J. Shah)

Partner

(M.No.45669)

UDIN: 21045669AAAABR1149



Media Release

## Lincoln Pharmaceuticals Ltd reports 31.35 % rise in the Standalone Net Profit at Rs. 13.37 crore in Q3 FY21

- Net revenues in Q3 FY21 at Rs. 113.26 crore, up 15.56 % from Rs. 98.01 crore in Q3 FY20
- Profit before Tax in Q3 FY21 at Rs. 18.16 crore, up 50.71 % from Rs. 12.05 crore in Q3 FY20
- Exports (FOB) in Q3 FY21 at Rs. 61.54 crore, up 4.00 % from Rs. 59.13 crore in Q3 FY20

### Financial Highlights (Standalone)

(Amount in Cr except EPS)

Particulars	Q3 FY21	Q3 FY20	Y-O-Y	9M FY21	9M FY20	Y-O-Y
Net Revenue	113.26	98.01	15.56%	339.77	307.65	10.44%
EBITDA	19.94	13.92	43.25%	71.37	58.45	22.12%
<b>Profit before Tax</b>	<b>18.16</b>	<b>12.05</b>	<b>50.71%</b>	<b>66.22</b>	<b>52.66</b>	<b>25.74%</b>
Net Profit	13.37	10.18	31.35%	48.56	40.33	20.74%
<b>E.P.S (Rs.)</b>	<b>6.68</b>	<b>5.09</b>	<b>31.35%</b>	<b>24.28</b>	<b>20.17</b>	<b>0.40%</b>

**February 02, 2021:** Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has reported net profit of Rs. 13.37 crore for the Q3 FY21 ended December 2020 as against net profit of Rs. 10.18 crore in the corresponding period last year, growth of 31.35%. Net revenue for the Q3 FY21 was reported at Rs. 113.26 crore, higher by 15.56% over previous fiscal's same period net revenue of Rs. 98.01 crore. Company reported EBITDA of Rs. 19.94 crore in Q3FY21, rise of 43.25% as compared to Rs. 13.92 crore in the corresponding period last year. EPS for Q3FY21 was at Rs. 6.68 per share for as compared to Rs. 5.09 in the corresponding period last year.

*Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "On back of strong domestic and international business, company posted 15.56 % sales growth, 4.00 % rise in exports and 31.35 % rise in the PAT for the quarter ended Q3FY21. Exports sales in nine months ended December 2020 was reported at Rs. 212.47 crore, growth of 17.56 % Y-o-Y. Geographical and product expansion coupled with operational efficiency contributing to the growth. Company is in the process of expanding presence in Africa, South East Asian countries and exploring entry in EU. Expanding the product basket, company will be introducing 6-7 new products in the domestic markets and expects 20-25 new dossiers approval for the exports market."*



Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288  
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, (Guj.) | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com

## Performance for Nine Months ended December 2020

As a result of expansion in geographical reach in domestic markets, relentless focus on exports and sustained marketing, the Net sales for the nine months ended December 2020 was reported at Rs.339.77 crore, higher by 10.44% over previous fiscal's same period net sales of Rs. 307.65 crore. Company reported Net profit of Rs. 48.56 crore for the nine months ended December 2020 as against net profit of Rs. 40.33 crore in the corresponding period last year, growth of 20.74 %. EPS for the 9MFY21 was reported at Rs. 24.28 per share. Exports for the 9MFY21 stood at Rs. 212.47 crore, up 17.56 % as against exports of Rs. 180.74 crore in 9MFY20.

To complement company's strong presence in acute segment, company is also building portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management and plans to introduce them in the EU markets. Company has received EU approval and plans to enter the region soon. Company currently exports to 60 plus countries and plans to expand to 90 plus countries in next 1-2 years.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.

\*\*\*



**Regd. Office :** "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India

**Phone :** +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288

**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

**Ta. :** Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com



Intertek

014



**About Lincoln Pharmaceuticals Limited: <https://www.lincolnpharma.com/>**

**Providing Affordable and Innovative medicines for healthier lives.**

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company have its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create **"Healthcare for All"**.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop with a capacity of producing 15 Lakh Power Unit Per annum in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization. Company's long term bank facilities are revised from A-/stable to A-/positive and short term bank facilities A2+by ICRA.

**For further information please contact:**

**Gopal Modi / Rupesh Panchal**  
ColdCoco Consultancy, Ahmedabad  
9099030184 / 9925023103  
gopal@coldcococonsultancy.com  
rupesh@coldcococonsultancy.com

**Darshit A. Shah (Chief Financial Officer)**  
Lincoln Pharmaceuticals Limited, Ahmedabad  
+91-79-4107-8048  
darshit@lincolnpharma.com



**Regd. Office :** "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
**Phone :** +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288  
**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

**Ta. :** Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com

